Research Progress on the Structure and Function, Immune Escape Mechanism, Antiviral Drug Development Methods, and Clinical Use of SARS-CoV-2 M

Overview

Journal Molecules

Publisher MDPI

Date 2025 Jan 25

PMID 39860219

Authors

Jiayi Ren

Zhengfu Zhang

Yi Xia

Daqun Zhao

Dingqin Li

Shujun Zhang

Affiliations

Soon will be listed here.

Abstract

The three-year COVID-19 pandemic 'has' caused a wide range of medical, social, political, and financial implications. Since the end of 2020, various mutations and variations in SARS-CoV-2 strains, along with the immune escape phenomenon, have emerged. There is an urgent need to identify a relatively stable target for the development of universal vaccines and drugs that can effectively combat both SARS-CoV-2 strains and their mutants. Currently, the main focus in treating SARS-CoV-2 lies in disrupting the virus's life cycle. The main protease (M) is closely associated with virus replication and maturation and plays a crucial role in the early stages of infection. Consequently, it has become an important target for the development of SARS-CoV-2-specific drugs. This review summarizes the recent research progress on the novel coronavirus's main proteases, including the pivotal role of M in the virus's life cycle, the structure and catalytic mechanism of M, the self-maturation mechanism of M, the role of M in virus immune escape, the current methods of developing antiviral drugs targeting M, and the key drugs that have successfully entered clinical trials. The aim is to provide researchers involved in the development of antiviral drugs targeting M with systematic and comprehensive information.

References

Huang C, Wei P, Fan K, Liu Y, Lai L . 3C-like proteinase from SARS coronavirus catalyzes substrate hydrolysis by a general base mechanism. Biochemistry. 2004; 43(15):4568-74. DOI: 10.1021/bi036022q. View

Dai W, Zhang B, Jiang X, Su H, Li J, Zhao Y . Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020; 368(6497):1331-1335. PMC: 7179937. DOI: 10.1126/science.abb4489. View

Kneller D, Galanie S, Phillips G, ONeill H, Coates L, Kovalevsky A . Malleability of the SARS-CoV-2 3CL M Active-Site Cavity Facilitates Binding of Clinical Antivirals. Structure. 2020; 28(12):1313-1320.e3. PMC: 7584437. DOI: 10.1016/j.str.2020.10.007. View

Singh E, Khan R, Jha R, Amera G, Jain M, Singh R . A comprehensive review on promising anti-viral therapeutic candidates identified against main protease from SARS-CoV-2 through various computational methods. J Genet Eng Biotechnol. 2020; 18(1):69. PMC: 7607901. DOI: 10.1186/s43141-020-00085-z. View

Abdelnabi R, Foo C, Jochmans D, Vangeel L, De Jonghe S, Augustijns P . The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern. Nat Commun. 2022; 13(1):719. PMC: 8847371. DOI: 10.1038/s41467-022-28354-0. View

de Vries M, Mohamed A, Prescott R, Valero-Jimenez A, Desvignes L, OConnor R . A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL inhibitor PF-00835231 as a potential new treatment for COVID-19. J Virol. 2021; 95(7). PMC: 8139662. DOI: 10.1128/JVI.01819-20. View

Ashraf U, Abokor A, Edwards J, Waigi E, Royfman R, Hasan S . SARS-CoV-2, ACE2 expression, and systemic organ invasion. Physiol Genomics. 2020; 53(2):51-60. PMC: 7900915. DOI: 10.1152/physiolgenomics.00087.2020. View

Shannon A, Selisko B, Le N, Huchting J, Touret F, Piorkowski G . Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat Commun. 2020; 11(1):4682. PMC: 7499305. DOI: 10.1038/s41467-020-18463-z. View

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

10.

Ebenezer O, Jordaan M, Ogunsakin R, Shapi M . Potential SARS-COV preclinical (in vivo) compounds targeting COVID-19 main protease: a meta-analysis and molecular docking studies. Hippokratia. 2021; 24(3):99-106. PMC: 8256780. View

11.

Plavec Z, Pohner I, Poso A, Butcher S . Virus structure and structure-based antivirals. Curr Opin Virol. 2021; 51:16-24. PMC: 8460353. DOI: 10.1016/j.coviro.2021.09.005. View

12.

Hu T, Zhang Y, Li L, Wang K, Chen S, Chen J . Two adjacent mutations on the dimer interface of SARS coronavirus 3C-like protease cause different conformational changes in crystal structure. Virology. 2009; 388(2):324-34. PMC: 7103376. DOI: 10.1016/j.virol.2009.03.034. View

13.

Dinda B, Dinda S, DasSharma S, Banik R, Chakraborty A, Dinda M . Therapeutic potentials of baicalin and its aglycone, baicalein against inflammatory disorders. Eur J Med Chem. 2017; 131:68-80. DOI: 10.1016/j.ejmech.2017.03.004. View

14.

Kraus T, Lau J, Parisien J, Horvath C . A hybrid IRF9-STAT2 protein recapitulates interferon-stimulated gene expression and antiviral response. J Biol Chem. 2003; 278(15):13033-8. DOI: 10.1074/jbc.M212972200. View

15.

Bharadwaj S, Lee K, Dwivedi V, Kang S . Computational insights into tetracyclines as inhibitors against SARS-CoV-2 M via combinatorial molecular simulation calculations. Life Sci. 2020; 257:118080. PMC: 7347340. DOI: 10.1016/j.lfs.2020.118080. View

16.

Mandal A, Jha A, Hazra B . Plant Products as Inhibitors of Coronavirus 3CL Protease. Front Pharmacol. 2021; 12:583387. PMC: 7985176. DOI: 10.3389/fphar.2021.583387. View

17.

Kil J, Lobarinas E, Spankovich C, Griffiths S, Antonelli P, Lynch E . Safety and efficacy of ebselen for the prevention of noise-induced hearing loss: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2017; 390(10098):969-979. DOI: 10.1016/S0140-6736(17)31791-9. View

18.

Tao R, Fang L, Bai D, Ke W, Zhou Y, Wang D . Porcine Reproductive and Respiratory Syndrome Virus Nonstructural Protein 4 Cleaves Porcine DCP1a To Attenuate Its Antiviral Activity. J Immunol. 2018; 201(8):2345-2353. DOI: 10.4049/jimmunol.1701773. View

19.

Szekely J, Mongkolprasert J, Jeayodae N, Senorit C, Chaimuti P, Swangphon P . Development, Analytical, and Clinical Evaluation of Rapid Immunochromatographic Antigen Test for SARS-CoV-2 Variants Detection. Diagnostics (Basel). 2022; 12(2). PMC: 8871278. DOI: 10.3390/diagnostics12020381. View

20.

Qian S, Fan W, Liu T, Wu M, Zhang H, Cui X . Seneca Valley Virus Suppresses Host Type I Interferon Production by Targeting Adaptor Proteins MAVS, TRIF, and TANK for Cleavage. J Virol. 2017; 91(16). PMC: 5533933. DOI: 10.1128/JVI.00823-17. View